

VOLUMEN 54

NUMERUS suppl 1

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2026

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Ivan Milas

Editors

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Martina Mikulandra – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Iva Andrašek, Gordana Brozović, Sanda Bubanović, Ljubica Luetić Cavor, Ljiljana Mayer, Aleksandar Milenović, Melita Perić Balja, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Marija Skoko, Danko Velimir Vrdoljak, Tiha Vučemilo

Editorial Council

M. Ban (Split, Croatia), M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), D. Danolić (Zagreb, Croatia), N. Đaković (Zagreb, Croatia), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), J. Koeva-Balabanova (Sofia, Bulgaria), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), I. Tomaš (Osijek, Croatia), S. Tomić (Split, Croatia), D. Vagić (Zagreb, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA).

This journal is indexed or abstracted by:

**SCOPUS, DOAJ, HRČAK, Scilit Basel, CrossReff, Index Copernicus, Google Scholar,
ResearchGate, JournalsPedia**

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 10 €. Annual subscription rates in Croatia: 45 € + VAT for institutions, 21 € + VAT for individuals and 10 € + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb



19. HRVATSKI ONKOLOŠKI KONGRES 19th CROATIAN ONCOLOGY CONGRESS

26.3.-29.3.2026.
Rovinj, Hotel Lone

Supplement editors:
Eduard Vrdoljak and Marijana Jazvić

Rovinj
March, 2026

ORGANIZER

Hrvatsko onkološko društvo – Hrvatski liječnički zbor
Croatian society of Oncology

Organizing committee:

President: Eduard Vrdoljak

Secretaries:

Antonio Juretić, Ingrid Belac Lovasić, Marija Ban

Lidija Beketić Orešković Sestre milosrdnice UHC, Miroslav Samaržija UHC Zagreb, Nina Dabelić Sestre milosrdnice UHC, Marko Zelić UHC Rijeka, Snježana Tomić UHC Split, Martina Bašić Koretić UHC Zagreb, Nina Dabelić Sestre milosrdnice UHC, Marko Jakopović UHC Zagreb, Boris Eužić Sestre milosrdnice UHC, Inga Marijanović UHC Mostar, Marijana Jazvić Sestre milosrdnice UHC, Ilijan Tomaš UHC Osijek, Vesna Bišof UHC Zagreb, Ana Frobe Sestre milosrdnice UHC, Kristina Katić UHC Zagreb, Mladen Solarić UHC Zagreb, Stipislav Jadrijević UH Merkur, Marijo Boban UHC Split, Marija Ban UHC Split, Josipa Flam UHC Osijek, Dag Zahirović UHC Rijeka, Tomislav Omrčen UHC Split, Mario Šekerija Croatian Institute of Public Health, Branka Petrić Miše UHC Split, Jasna Radić Sestre milosrdnice UHC, Ivana Canjko UHC Osijek, Majana Soče UHC Zagreb

Scientific committee:

Tanja Badovinac-Črnjević Croatian society of Oncology, Goran Golčić UHC Rijeka, Davor Štimac UHC Rijeka, Boris Ružić Sestre milosrdnice UHC, Sven Seiwerth UHC Zagreb, Hrvoje Šobat Radiochirurgia Zagreb, Ariana Znaor Croatian National Cancer Registry

Sponsors and exhibitors:

Abbott	Medicopharmacia
Abbvie	Medis
Amgen	Medison Pharma
Astellas	Merck
AstraZeneca	MSD
BauschHealth	Novartis
Bayer	Oktal Pharma
EL PHARMA	Pfizer
Ewopharma	Pharmas
Genesis Pharma Adriatic	Roche
J&J	Sandoz
Lilly	Servier
Medicina danas	Sqilline Business Solutions OOD

CONTENTS

ORAL PRESENTATIONS

Anuška Budisavljević	
S1 – Antibody-drug conjugates for breast cancer treatment	3
Mirela Šambić Penc, Maja Kovač Barić, Maja Drežnjak Madunić, Zdravka Krivdić Dupan, Luka Perić, Tara Cvijić Perić, Dino Belić, Sebastijan Spajić, Dominik Seletković, Dora Muršić, Vedrana Pavlović, Laura Zahirović, Ivana Canjko	
S2 – Bladder preservation strategy in muscle invasive disease	5
Mario Šekerija, Petra Čukelj	
S3 – Cancer prevalence in Croatia – how many people are living with a cancer diagnosis?.	7
Anamarija Kovač Peić, Ivana Canjko	
S4 – Case report of patient with metastatic EGFR mutated lung cancer and successful treatment based on comprehensive genomic profiling	9
Ivana Canjko, Mirela Šambić Penc, Maja Kovač Barić, Zdravka Krivdić Dupan, Luka Perić, Sebastijan Spajić, Dominik Seletković, Laura Zahirović, Vedrana Pavlović	
S5 – Combination of targeted therapy and radiotherapy in the treatment of metastatic non-small cell lung cancer	10
Jasna Radić	
S6 – First-line immunotherapy for metastatic non-small cell lung cancer: how to choose between so many options?	11
Majana Soče	
S7 – How to optimize multidisciplinary treatment of oligometastatic colorectal cancer?.	12
Kristina Katić	
S8 – Immunotherapy in the treatment of cervical cancer: a turning point in outcomes?	14
Marijana Jazvić, Marijana Udovičić, Jure Murgić, Ana Fröbe	
S9 – Personalizing first-line treatment for metastatic urothelial carcinoma	16
Marijana Milović-Kovačević	
S10 – Precision oncology in the treatment of endometrial cancer.	18

Jasenka Gugić	
S11 – Radiotherapy in breast cancer in patients initially treated with neoadjuvant systemic therapy	20
Lana Jajac Bručić	
S12 – Therapeutic challenges and rare complications of immunotherapy in metastatic renal cell carcinoma – case reports	22
Josipa Flam, Andreja Bartulić, Luka Perić, Vedrana Pavlović, Laura Zahirović, Dino Belić, Ilijan Tomaš	
S13 – The era of precision oncology in the treatment of biliary tract tumors	24
Marijo Boban	
S14 – Treatment approaches for stage III patients in the immunotherapy era	25
 POSTER PRESENTATIONS	
Ante Strikić, Žana Saratlija, Pavle Jovović, Tomislav Omrčen, Zdravka Rakuljić, Ana Majić, Bisera Mamić, Antonia Perković, Mario Duvnjak, Marijan Šitum	
P1 – 1 cohort, 2 ministries, 3 specialties: synergy of systems in the treatment of patients with radiation-induced hemorrhagic cystitis with hyperbaric oxygen therapy	29
Jelena Šuto Pavičić, Tomislav Omrčen, Eduard Vrdoljak	
P2 – Adjuvant pembrolizumab in clear cell renal cell carcinoma (CCRCC): single-institution and tertiary cancer center experience.	31
Lidija Pavlović, Milana Matović, Simonida Bobić, Anđela Karaferić, Marijana Milović-Kovačević	
P3 – Anti-angiogenic therapy beyond chemoresistance: bevacizumab in advanced low-grade serous ovarian carcinoma – real-world experience from Serbia	32
Marica Barač, Marija Pancirov, Josipa Flam, Dora Čerina Pavlinović, Matea Jakas Vučić, Natalija Dedić Plavetić, Paula Podolski, Mladen Krnić, Žarko Bajić, Eduard Vrdoljak	
P4 – Baseline metabolic risk factors and adjusted treatment effects on grade 3–4 hyperglycemia during alpelisib therapy: covariate models from the ITACA randomized phase IIB trial	34
Hrvoje Brčić, Jure Murgić, Angela Prgomet Sečan, Dora Franceschi, Marin Prpić, Ana Fröbe	
P5 – Biochemical and metastasis-free survival after post-prostatectomy salvage radiotherapy: updated analysis and impact of concomitant ADT and fractionation in a single-centre retrospective cohort	35
Dora Antunović, Marijana Jazvić, Željko Soldić, Kristina Urch, Ana Fröbe	
P6 – CDK4/6 inhibitors as adjuvant therapy in the treatment of early-stage breast cancer – single institution experience.	37

Matea Vukić, Hrvoje Brčić, Fran Ivan Madunić, Jasna Radić, Jasmina Marić Brozić, Davor Kust, Marin Šunjić, Željko Soldić, Ana Fröbe P7 – Characteristics and outcomes of patients with gastrointestinal tumors under 50 years of age – a single-center experience	39
Bartul Vuković, Ivan Viculin, Josip Vrdoljak, Krešimir Tomić, Ivana Canjko, Dora Čerina Pavlinović, Mateo Ćurin, Lidija Bošković, Niko Dunkić, Vide Popović, Suzana Mladinov, Joško Božić, Eduard Vrdoljak P8 – Comparative performance of large reasoning models and human multidisciplinary teams in lung cancer decision-making	40
Teo Buhovac, Martina Mladinović, Mario Nalbani, Sanda Čale, Anita Kajić-Selak, Eduard Vrdoljak P9 – Complementary therapies in early breast cancer: evidence-based decisions of Croatian oncologists	41
Fran Ivan Madunić, Jasna Radić, Jasmina Marić Brozić, Davor Kust, Marin Šunjić, Željko Soldić, Ana Fröbe P10 – Comprehensive genomic profiling (CGP) of gastrointestinal cancers: updated single institution experience from Croatia	43
Ana Puđa, Jure Murgić, Angela Prgomet Sečan, Marin Prpić, Dora Franceschi, Tomislav Omrčen, Petar Suton, Mirela Šambić Penc, Maja Drežnjak Madunić, Slavica Zubčić Krišto, Ivo Dilber, Mihaela Trajbar, Ljubica Vazdar, Antonija Salamun, Monika Ulamec, Ivan Šamija, Ivana Čelap, Snježana Dotlić, Ana Fröbe P11 – Comprehensive genomic profiling in advanced prostate cancer: second update from Croatian Uro-Oncology Group (CUOG)	44
Teo Buhovac, Ana Parić, Maja Pezer Naletilić, Krešimir Tomić, Monika Glibić, Anita Kajić-Selak, Eduard Vrdoljak P12 – Decision-making on complementary therapies in early breast cancer: evidence alignment among Bosnia and Herzegovina oncologists	46
Laura Radošić, Ana Bešvir Džubur, Lea Juras, Alojzije Košić, Tihana Salopek, Laura Radoš, Sara Matulić Čubranić, Ines Mujčin, Ana Glavan Ćosić, Petra Cotić, Doris Kolovrat, Ana-Marija Bukovica Petrc, Iva Skočilić, Ivana Mikolašević P13 – Development and implementation of the first dedicated intensive care unit for oncology patients in Croatia	47
Josip Vrančić P14 – Divergent temporal trends in early non-breast second primary malignancies following breast cancer: a 25-year seer analysis	49
Matea Jakas Vučić, Marija Pancirov, Josipa Flam, Dora Čerina Pavlinović, Marica Barač, Natalija Dedić Plavetić, Paula Podolski, Mladen Krnić, Žarko Bajić, Eduard Vrdoljak P15 – Does reducing hyperinsulinemia feedback improve outcomes of PI3KA inhibition? Exploratory efficacy signals from the ITACA trial	50

Lidija Bošković, Matea Buljubašić Franić, Lana Bekavac, Darijo Hrepić, Eduard Vrdoljak P16 – Durvalumab in the first-line treatment of advanced biliary tract cancer: single center experience at the Department of Oncology and Radiotherapy, University Hospital Split	52
Kristina Katić, Dejan Čičak, Josip Kuharić, Suzana Lide-Škalec, Vanda Paradžik Pašalić, Anastazija Aleksandrova Stanojević, Ida Čepulić Maravić, Ana Magličić, Goran Vujić, Joško Lešin, Pavao Planinić, Ivan Babić, Marko Škvorc, Ivo Brozović, Helena Lovrić, Mirna Ivandić Lončar, Davor Petrović, Marija Milković Periša P17 – Efficacy and safety of immunotherapy in previously chemotherapy treated patients with recurrent endometrial cancer	53
Doris Kolovrat, Alojzije Košić, Dag Zahirović, Tihana Salopek, Sara Matulić Čubranić, Ines Mujčin, Laura Radošić, Laura Radoš, Petra Cotić, Jasna Marušić, Sanja Ropac, Lana Bolf Perić, Ana-Marija Bukovica Petrc, Maja Kolak Radojčić, Iva Skočilić, Marin Golčić, Anita Beg, Paula Požgaj Marija, Ivana Mikolašević P18 – Establishing a stereotactic radiotherapy program: initial experience of the Tumor Clinic at Clinical Hospital Center Rijeka	54
Niko Dunkić, Bartul Vuković, Dora Čerina Pavlinović, Lidija Bošković, Eduard Vrdoljak, Ivan Viculin, Mateo Ćurin, Suzana Mladinov, Vide Popović, Joško Božić, Josip Vrdoljak, Krešimir Tomić, Ivana Canjko P19 – Evaluating large reasoning models versus human multidisciplinary teams in lung cancer decision-making: a real-world study	56
Sara Matulić Čubranić, Marin Golčić, Iva Skočilić, Maja Kolak Radojčić, Sanja Ropac, Lana Bolf Perić, Irena Krznarić Zrnić, Petra Cotić, Laura Radoš, Laura Radošić, Alojzije Košić, Tihana Salopek, Ani Mihaljević Ferari, Ines Mujčin, Doris Kolovrat, Marina Šantić, Goran Hauser, Robert Žmirić, Nika Zubalj, Ivana Mikolašević P20 – Fecal microbiota transplantation for the treatment of immune-mediated colitis as a consequence of immunotherapy – a single center experience	58
Tihana Salopek, Andrej Belančić, Marin Golčić, Iva Skočilić, Maja Kolak Radojčić, Ana-Marija Bukovica Petrc, Nina Poropat, Sandra Peternel, Larisa Prpić Massari, Iris Vuković, Ante Tolić, Irena Krznarić Zrnić, Melita Kukuljan, Tea Vrdoljak, Jelena Šimić, Tatjana Zekić, Sara Matulić Čubranić, Petra Cotić, Laura Radoš, Laura Radošić, Alojzije Košić, Doris Kolovrat, Ines Mujčin, Sara Francetić, Lea Juras, Ana Bešvir Džubur, Karla Lisica, Ivana Mikolašević P21 – First multidisciplinary toxicity team for cancer immunotherapy-related adverse events in Croatia – centre feasibility and clinical experience	59

Ana Puđa, Mirela Kekić, Jure Murgić, Marijana Jazvić, Marija Gamulin, Milena Gnjiđić, Ivo Dilber, Slavica Zubčić Krišto, Maja Drežnjak Madunić, Mirela Šambić Penc, Tomislav Omrčen, Antonija Salamun, Anuška Budisavljević, Lana Jajac Bručić, Dag Zahirović, Zvonko Curić, Mihaela Trajbar, Ljubica Vazdar, Petar Suton, Anamarija Kovač Peić, Monika Ulamec, Igor Tomašković, Ana Fröbe	
P22 – Genomic determinants of outcomes during avelumab maintenance in advanced urothelial carcinoma: real-world genomic insights from the Croatian uro-oncology group	61
Vid Duplančić, Ana Bobinac, Luka Vončina, Katarina Hraste, Ana Tečić Vuger, Robert Šeparović, Eduard Vrdoljak	
P23 – Health-related quality of life among working-age women with breast cancer in Croatia: a multicentre cross-sectional study using EQ-5D-5L and EORTC QLQ-BR23	63
Maja Erceg Tušek, Ljiljana Vukota	
P24 – How did oncology patients in Croatia experience oncology care pathway in 2025?	64
Morena Kurtović, Tomislav Omrčen	
P25 – Hypofractionated radiotherapy for prostate cancer – experience from the Department of Oncology and Radiotherapy, University Hospital Center Split . . .	65
Anđela Karaferić, Lidija Pavlović, Simonida Bobić, Milana Matović, Slobodan Kutić, Jelena Jovanović, Jovana Mijucić, Marijana Milović-Kovačević	
P26 – Immune-related adverse events and clinical outcomes of first-line pembrolizumab in advanced cervical cancer.	67
Lela Bitar, Fran Seiwerth, Lidija Ljubičić, Ana Bačelić-Gabelica, Olivera Maletić, Dražena Srđić, Bernard Budimir, Filip Popović, Maja Hrabak-Paar, Sanja Pleština, Miroslav Samaržija, Marko Jakopović	
P27 – Immunotherapy in PD-L1–HIGH metastatic non–small cell lung cancer: real-world results from a single Croatian academic center	68
Natko Čović, Zvonimir Družianić, Darijo Hrepić, Eduard Vrdoljak	
P28 – Impact of steroid daily dose at start of radiotherapy on survival in patients with glioblastoma: a single-center retrospective analysis	69
Zvonimir Družianić, Natko Čović, Darijo Hrepić, Eduard Vrdoljak	
P29 – Impact of time to postoperative chemoradiotherapy on survival in patients with glioblastoma: a single-center retrospective analysis	71
Vid Duplančić, Ana Bobinac, Luka Vončina, Katarina Hraste, Ana Tečić Vuger, Robert Šeparović, Eduard Vrdoljak	
P30 – Indirect economic burden of breast cancer among working-age women in Croatia: productivity losses, informal care and monetised morbidity-related welfare loss	72
Milka Vještica	
P31 – Lymphocytic infiltration in prostate cancer	74

Aja Džaferović, Chiara Viktoria Grbeša, Kristian Krpina	
P32 – Metastatic laesions in urinary bladder: case series and literature review	75
Mia Mihoković, Karla Rogić, Irma Stilinović, Mislav Habijanec, Mia Mihaljević Mitar, Višnja Gregov, Sara Bilić Knežević, Martina Bašić Koretić, Ana Roguljić Guteša, Mirna Ravlić, Antonio Juretić, Petar Suton	
P33 – Metastatic clear cell renal cell carcinoma: real world evidence from Comprehensive Oncology Centre in Croatia	77
Sara Jaman, Fabijan Jelovčić, Borna Arsov, Majana Soče, Spomenka Mikuš, Vesna Bišof	
P34 – MRI restaging after total neoadjuvant therapy: how accurate is it in locally advanced rectal cancer?	78
Tara Cvijić Perić, Josipa Flam, Ilijan Tomaš, Kristina Kralik, Mirela Šambić Penc, Ivana Canjko, Maja Kovač Barić, Sebastijan Spajić, Dominik Seletković, Darko Kotromanović, Luka Perić, Dora Muršić, Dino Belić, Laura Zahirović, Vedrana Pavlović	
P35 – Neoadjuvant therapy of triple – negative breast cancer – a five – year single – center experience	79
Marica Barać, Marija Pancirov, Josipa Flam, Dora Čerina Pavlinović, Matea Jakas Vučić, Natalija Dedić Plavetić, Paula Podolski, Mladen Krnić, Žarko Bajić, Eduard Vrdoljak	
P36 – Optimizing alpelisib tolerability through evening dosing and short fasting: results of the randomized ITACA phase IIB trial	81
Lana Ljubičić, Krešimir Jemrić, Katarina Antunac, Maja Baučić	
P37 – Prevalence of IDH mutated gliomas, patient characteristics and treatment modalities	82
Lana Bekavac, Katarina Hraste, Vid Duplančić, Andrija Katić, Darijo Hrepić, Eduard Vrdoljak	
P38 – Prognostic value of baseline neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma, treated with atezolizumab plus bevacizumab: a single-center real-world analysis	83
Dora Čerina Pavlinović, Lidiya Bošković, Matea Buljubašić Franić, Josipa Bilobrk, Zdravka Rakuljić, Ivana Tica Sedlar, Marija Ban, Jelena Viculin, Ante Strikić, Andrija Katić, Ana Majić, Bisera Mamić, Iva Čutura, Branka Petrić Miše, Marijo Boban, Tomislav Omrčen, Eduard Vrdoljak	
P39 – Real-world impact of comprehensive genomic profiling – guided therapy on advanced solid tumors: insights from a single-institution cohort.	85
Ana Parić, Krešimir Tomić, Maja Pezer Naletilić, Teo Buhovac, Sanda Čale, Inga Marijanović, Eduard Vrdoljak, Zoran Gatalica, Semir Vranić	
P40 – Real-world implementation of next-generation sequencing in gynecological cancers: preliminary data from the University Clinical Hospital Mostar	86

Matea Jakas Vučić, Marija Pancirov, Josipa Flam, Dora Čerina Pavlinović, Marica Barać, Natalija Dedić Plavetić, Paula Podolski, Mladen Krnić, Žarko Bajić, Eduard Vrdoljak P41 – Quality of life with evening alpelisib dosing and fasting: patient-reported outcomes from the ITACA study	87
Zdravka Krivdić Dupan, Jasmina Rajc, Irena Zagorac, Tomislav Kizivat, Silva Guljaš, Mirela Šambić Penc, Laura Zahirović, Ivan Erić, Darija Šnajder Mujkić, Tatjana Ladenhauser, Marin Štefančić, Sebastijan Spajić, Ivana Canjko P42 – Radiological evaluation of response to neoadjuvant therapy in non-small cell lung cancer: radiological–pathological correlation – experience from University Hospital Center Osijek	88
Katarina Hraste, Lana Bekavac, Vid Duplančić, Darijo Hrepić, Eduard Vrdoljak, Andrija Katić P43 – Real-world clinical outcomes of atezolizumab plus bevacizumab in unresectable or metastatic hepatocellular carcinoma: a single-center retrospective study	89
Katarina Božić, Jure Murgić, Angela Prgomet Sečan, Marijana Jazvić, Monika Ulamec, Pero Bokarica, Igor Tomašković, Ana Fröbe P44 – Real-world treatment patterns for advanced urothelial cancer in the era of immunotherapy and antibody-drug conjugates: a single-institution analysis.	91
Dora Čerina Pavlinović, Kristina Katić, Ivana Tica Sedlar, Branka Petrić Miše, Robert Šeparović, Ana Fröbe, Ivana Mikolašević, Ilijan Tomaš, Eduard Vrdoljak P45 – Shaping gynecologic tumor management: comprehensive genomic-guided therapy results from everyday clinical practice across the nation.	93
Lidija Ljubičić, Lela Bitar, Ana Andrić, Fran Seiwerth, Dražena Srđić, Zoran Janevski, Goran Madžarac, Ivana Kuhtić, Maja Hrabak-Paar, Sonja Badovinac, Silvana Smojver-Ježek, Ana Mataić, Miroslav Samaržija, Marko Jakopović P46 – Single-center experience with neoadjuvant chemoimmunotherapy in resectable NSCLC.	94
Ines Mujčin, Marin Golčić, Iva Skočilić, Dag Zahirović, Ani Mihaljević Ferari, Sanja Ropac, Lana Bolf Perić, Ana-Marija Bukovica Petrc, Petra Cotić, Laura Radoš, Laura Radošić, Alojzije Košić, Tihana Salopek, Sara Matulić Čubranić, Doris Kolovrat, Jasna Čačić, Gordana Grubišić, Zumreta Čurić, Ivana Mikolašević P47 – Sodium hyaluronan butyrate for the prevention of radiation proctitis: a randomized, placebo-controlled study.	95
Marijo Boban, Luka Grubišić, Zvonimir Boban, Matea Buljubašić Franić, Suzana Mladinov, Eduard Vrdoljak P48 – Targeted therapy for patients with advanced ALK-positive non-small cell lung cancer – single center experience	97
Fran Seiwerth, Lela Bitar, Lidija Ljubičić, Dražena Srđić, Slavica Liška, Marta Koršić, Miroslav Samaržija, Marko Jakopović P49 – Ten-year follow-up of lung cancer patients diagnosed at a tertiary center in Croatia: a retrospective cohort study	98

<p>Laura Zahirović, Marko Pisačić, Sebastijan Spajić, Dora Muršić, Tara Cvijić Perić, Dominik Seletković, Vedrana Pavlović, Luka Perić, Dino Belić, Mirela Šambić Penc, Ivana Canjko, Josipa Flam, Ilijan Tomaš</p> <p>P50 – The difference in KI67 before and after neoadjuvant chemotherapy in breast cancer</p>	99
<p>Krešimir Tomić, Sanda Čale, Maja Pezer Naletilić, Gordana Berić Jozić, Marija Perić, Ema Voloder, Monika Glibić, Semir Vranić, Eduard Vrdoljak</p> <p>P51 – The role of the lung immune prognostic index (LIPI) in real-world patients with extensive-stage small-cell lung cancer</p>	101
<p>Dino Belić, Luka Perić, Sebastijan Spajić, Laura Zahirović, Dominik Seletković, Ilijan Tomaš, Mirela Šambić Penc, Josipa Flam</p> <p>P52 – Duration of CDK4/6 inhibitor therapy in patients with metastatic breast cancer and subsequent treatment options</p>	102
<p>Lucija Zeljko, Jasmina Marić Brozić, Nina Dabelić, Kristina Urch, Marin Šunjić, Ana Fröbe</p> <p>P53 – Treatment of patients with locally advanced and/or metastatic cutaneous squamous cell carcinoma (CSCC) with cemiplimab as first-line systemic therapy – initial experiences from the Department of Oncology and Nuclear Medicine at Sestre Milosrdnice University Hospital Center.</p>	103
<p>Sebastijan Spajić, Ivana Canjko, Dino Belić, Luka Perić, Tara Cvijić Perić, Vedrana Pavlović, Laura Zahirović, Mirela Šambić Penc, Zdravka Krivdić Dupan, Ilijan Tomaš</p> <p>P54 – Treatment outcomes of patients with extensive-stage small cell lung cancer (ES-SCLC) treated with atezolizumab – a single center experience</p>	105
<p>Ana Glavan Ćosić, Ana-Marija Bukovica Petrc, Maja Kolak Radojčić, Sanja Ropac, Marin Golčić, Petra Cotić, Laura Radoš, Laura Radošić, Alojzije Košić, Sara Matulić Čubranić, Ines Mujčin, Tihana Salopek, Jelena Lazarić, Ingrid Rudić, Kaja Šimunović, Ljubica Đozlija, Manda Švabić, Ivana Mikolašević</p> <p>P55 – What do we lose when DIBH fails? A six-month retrospective analysis of heart, lad and left lung doses in left-sided breast radiotherapy</p>	106
<p>Doris Kolovrat, Alojzije Košić, Tihana Salopek, Sara Matulić Čubranić, Ines Mujčin, Laura Radoš, Laura Radošić, Petra Cotić, Manda Kolacio Svabić, Nevena Obajdin, Jasna Marušić, Sanja Ropac, Lana Bolf Perić, Ana-Marija Bukovica Petrc, Maja Kolak Radojčić, Iva Skočilić, Marin Golčić, Blanka Josipović, Doris Keđo, Ivan Gračan, Ivana Mikolašević</p> <p>P56 – Whole brain radiation with hippocampal avoidance plus memantine: initial experience of the Tumor Clinic at Clinical Hospital Centre Rijeka</p>	107